Aarti Drugs Ltd.

NSE: AARTIDRUGS | BSE: 524348

Mid-range Performer

Download real time

491.60 3.55 (0.73%)

57.56% Gain from 52W Low

71,689 NSE+BSE Volume

NSE 03 Oct, 2025 3:31 PM (IST)

4,486.8

Market Cap

Above industry Median

0.8

Beta 1Year

Low volatility

Aarti Drugs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AARTIDRUGS, BSE:524348 Aarti Drugs Ltd.

Search Inside the pdf :

Aarti Drugs Ltd.

08 May 2025

491.60

0.73%

Result Update:Aarti Drugs

buy

Buy: Aarti Drugs Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock.

Aarti Drugs Ltd. has gained 41.06% in the last 6 Months

Aarti Drugs Ltd.

30 Jan 2025

491.60

0.73%

Result Update:Aarti Drugs

buy

Buy: Aarti Drugs Ltd.

Target

Axis Direct

We maintain our recommendation of BUY on the stock.

Number of FII/FPI investors decreased from 96 to 73 in Jun 2025 qtr

Aarti Drugs Ltd.

29 Oct 2024

491.60

0.73%

Result Update:Aarti Drugs

buy

Buy: Aarti Drugs Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock.

Aarti Drugs Ltd. is trading below its 30 day SMA of 492.6

Aarti Drugs Ltd.

30 Jul 2024

491.60

0.73%

Result Update:Aarti Drugs

buy

Buy: Aarti Drugs Ltd.

Target

Axis Direct

We have BUY on the stock

Number of FII/FPI investors decreased from 96 to 73 in Jun 2025 qtr

Aarti Drugs Ltd.

20 May 2024

491.60

0.73%

Pick of the Week:21 MAY 2024

buy

Buy: Aarti Drugs Ltd.

Target

Axis Direct

We recommend a BUY rating on the stock with a target price of Rs 536/share, implying an upside of 10% from CMP

Aarti Drugs Ltd. is trading below its 30 day SMA of 492.6

Aarti Drugs Ltd.

07 May 2024

491.60

0.73%

Result Update:Aarti Drugs

buy

Buy: Aarti Drugs Ltd.

Axis Direct

Company Outlook & Guidance: In the API sector, a positive shift in the export landscape is anticipated in the near future, supported by interest rate reductions, low stock levels, and an upswing in demand. We have BUY on stock

Number of FII/FPI investors decreased from 96 to 73 in Jun 2025 qtr

Aarti Drugs Ltd.

29 Jan 2024

491.60

0.73%

Result Update:Aarti Drugs

buy

Buy: Aarti Drugs Ltd.

Target

Axis Direct

It is expected that API's realisations could be on lower side along elevated key solvents as the industry is facing oversupply.

Aarti Drugs Ltd. has gained 41.06% in the last 6 Months

Aarti Drugs Ltd.

20 Oct 2023

491.60

0.73%

Result Update:Aarti Drugs

buy

Buy: Aarti Drugs Ltd.

Target

Axis Direct

We expect demand for API to continue in the upcoming quarters with easing supply chain bottlenecks. We believe that Aarti Drugs, being a leader in the domestic industry, is well-placed to capitalize on prevalent as well as future growth opportunities.

Aarti Drugs Ltd. has an average target of 475.00 from 1 broker.

Aarti Drugs Ltd.

25 Jul 2023

491.60

0.73%

Result Update:Aarti Drugs

buy

Buy: Aarti Drugs Ltd.

Target

Axis Direct

We believe that Aarti Drugs, being a leader in the domestic industry, is well-placed to capitalize on prevalent as well as future growth opportunities. We have BUY rating on stock.

Aarti Drugs Ltd. is trading below its 30 day SMA of 492.6

Aarti Drugs Ltd.

24 Jun 2023

491.60

0.73%

Aarti Drugs | Plant Visit Note

buy

Mgmt Note: Aarti Drugs Ltd.

Edelweiss

Multiple capex nearing completion

Number of FII/FPI investors decreased from 96 to 73 in Jun 2025 qtr

Is Aarti Drugs Ltd. worth buying?

745 Votes:

Buy 77.85%

Sell 11.41%

Hold 10.74%

RESEARCH REPORTS

Buy SEE REPORTS >

Buy SEE REPORTS >